Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoGenix, a biopharmaceutical company, has appointed Lex Cowsert as its new president, CEO, and director.
Subscribe to our email newsletter
Randy Moseley, who was serving as interim CEO until a permanent replacement was named, simultaneously resigned as interim CEO but will continue in his role as chairman of the board and principal financial officer.
The appointment of Dr Cowsert significantly strengthens CytoGenix’s management team as the company enters a new stage in corporate development. Dr Cowsert will lead the team at CytoGenix to implement a stronger business and commercialization plan, and tighter revenue generating strategies during this new phase of development.
Dr Cowsert is currently a co-founder and serves as the chief scientific officer of BellairePharma. Dr Cowsert has received his BS in biology from the University of Florida and earned his PhD in molecular biology from Georgetown University.
Mr Moseley said: “We are delighted that Dr Cowsert is joining the team to lead CytoGenix in this exciting stage of growth and expansion. His industry expertise in commercialization and business development complements our current management team and brings a new and more directed business approach to the company.”